Meningococcal Vaccine Market

1
Meningococcal Vaccine Market

• Meningococcal Vaccine Market to Reach 4.19 Bn,
  Globally, by 2026 Allied Market Research

2
Prime Determinants of Growth  ?
As per the report published by Allied Market
Research, the global Meningococcal Vaccine
Industry garnered 1.93 billion in 2018, and is
projected to garner 4.19 billion by 2026,
witnessing a CAGR of 9.5 from 2019 to 2026. The
report provides a detailed analysis of the top
investment pockets, top winning strategies,
drivers opportunities, market size
estimations, competitive landscape, and changing
market trends.
3
(No Transcript)
4
Covid-19 scenario

• The global lockdown has paused the immunization
  programs. However, in certain regions the program
  schedules would be changed. In addition, the RD
  processes for vaccine technology have come to a
  halt. Moreover, in a Covid-19 trial conducted by
  the University of Oxford, meningococcal medicine
  has been used as a placebo effect.

5
Leading Market Players?

• GlaxoSmithKline Plc
• Hualan Biological Engineering Inc.
• Incepta Pharmaceuticals Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd
• Walvax Biotechnology Co., Ltd.
• Bio-Manguinhos
• Bio-Med Pvt. Limited.

6
Contact

• David Correa
• 5933 NE Win Sivers Drive205, Portland,
  OR 97220United StatesToll Free
  1-800-792-5285 UK 44-845-528-1300Hong Kong
  852-301-84916India (Pune) 91-20-66346060Fax
  1-855-550-5975help_at_alliedmarketresearch.comWeb
   https//www.alliedmarketresearch.com  Follow Us
  on LinkedIn Twitter